Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide IV every 4 weeks plus oral dolutegravir in virologically suppressed HIV-1 infection
ChiCTR2300073588Phase 4
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of albuvirtide in human immunodeficiency virus infection (HIV). Primary endpoints: Cmax and Cthrough.
02
Drugs
albuvirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2300073588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073588.